Skip to main content
. 2017 Mar 29;8(19):31993–32008. doi: 10.18632/oncotarget.16669

Figure 2. miR-29a inhibits RPC proliferation.

Figure 2

(A) The qPCR results revealed that the expression of miR-29a was sharply upregulated by transfection of RPCs with the miR-29a mimic and significantly downregulated by the miR-29a inhibitor treatment. (B) According to the qPCR analysis, the expression of Ki67 (a cell proliferation marker) and vimentin, Pax6 and nestin (retinal progenitor markers) decreased in the miR-29a mimic-treated RPCs and increased when the RPCs were treated with the miR-29a inhibitor. (C) The results of the western blotting analysis were consistent with the qPCR analysis. Western blotting bands were scanned and normalized to β-actin. (D) The proliferation ability of the RPCs was assessed via a CCK-8 analysis. The proliferation ability of the RPCs markedly increased when treated with the miR-29a inhibitor and decreased when treated with the miR-29a mimic under proliferation conditions. (E, F) Immunostaining with antibodies against Ki67 and nestin revealed the effects on RPC proliferation, and was consistent with the results shown above. These data are averages of three independent experiments. Scale bars: 100 μm. Data are averages of three independent experiments. Error bars indicate the standard error of the mean. *P ≤ 0.05 (Student's t-test).